GENFIT to Present at H.C. Wainwright Conference Amid Liver Disease Focus
Event summary
- GENFIT to present at H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 11:00am ET.
- Presentation and 1-on-1 meetings to be held in New York City.
- Replay accessible via GENFIT's Investor Relations website.
- GENFIT focuses on rare, life-threatening liver diseases, including ACLF, AD, and HE.
- Company's lead product, Iqirvo® (elafibranor), received accelerated approval in 2024 for PBC treatment.
The big picture
GENFIT's participation in the H.C. Wainwright conference comes as the biopharmaceutical company seeks to expand its footprint in rare liver disease treatments. With Iqirvo® now commercially available, GENFIT is positioning itself as a key player in the PBC market, while also advancing its pipeline in other high-need areas like ACLF and CCA. The company's strategic focus on both therapeutic and diagnostic solutions underscores its commitment to addressing unmet medical needs in liver disease.
What we're watching
- Commercialization Strategy
- How GENFIT will leverage the conference to drive adoption of Iqirvo® in the PBC market.
- Pipeline Progress
- Whether GENFIT can sustain momentum in its R&D portfolio beyond Iqirvo®.
- Investor Sentiment
- The pace at which GENFIT can convert investor interest into tangible partnerships or funding.
Related topics